FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine and concerns a fibrosis inhibitor containing 2-{4-N-(5,6-diphenyl-pyrazin-2-yl)-N-isopropylamino]butyloxy}acetic aci or a pharmaceutically acceptable salt thereof or 2-{4-[N-(5,6-diphenyl-pyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulphonyl)acetamide or a pharmaceutically acceptable salt thereof as an active ingredient for treating interstitial pneumonia, pulmonary fibrosis, scleroderma or hepatic cirrhosis.
EFFECT: inhibitor provides high efficacy.
6 cl, 0 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE CAPABLE OF BINDING WITH β AND INHIBITING BIOLOGICAL ACTIVITY OF β IN VITRO AND/OR IN VIVO, APPLICATION OF PEPTIDE, PHARMACEUTICAL COMPOSITION, DNA SEQUENCE, DNA STRUCTURE, EXPRESSION VECTOR, HOST-CELL AND METHOD OF OBTAINING PEPTIDE | 2004 |
|
RU2333917C2 |
| USE OF DNA SEQUENCE WHICH CODES PEPTIDE ABLE TO BIND WITH TRANSFORMING GROWTH FACTOR β1 (VERSIONS) | 2008 |
|
RU2455358C2 |
| PREVENTIVE OR THERAPEUTIC AGENT FOR TREATING FIBROSIS | 2011 |
|
RU2583290C2 |
| ANTISENSE OLIGONUCLEOTIDES AS INHIBITORS OF SIGNAL PATH TGF-R | 2015 |
|
RU2717454C2 |
| APPLICATION OF CB1 RECEPTOR ANTAGONISTS FOR PREPARATION OF COMPOSITION APPLICABLE FOR TREATMENT OF HEPATIC DISEASES | 2005 |
|
RU2402328C2 |
| INHIBITORS OF SIGNAL TRANSMISSION OF TRANSFORMING GROWTH FACTORS (TGF-R) FOR TREATMENT OF CNS DISORDERS | 2005 |
|
RU2385933C2 |
| USE OF CHIGLITAZAR AND RELATED COMPOUNDS | 2019 |
|
RU2769446C1 |
| APPLICATION OF INHIBITING TGF-beta1 PEPTIDES FOR PREPARATION OF AGENT MODULATING IMMUNE RESPONSE | 2005 |
|
RU2420307C2 |
| DRUG FOR TREATMENT OF TISSUE FIBROSIS BASED ON COMPONENTS OF SECRETOME OF MESENCHYMAL STROMAL CELLS, METHOD FOR OBTAINING AND APPLYING REMEDY | 2020 |
|
RU2766707C1 |
| ANTIFIBROGENIC COMPOUNDS, METHODS AND USE THEREOF | 2014 |
|
RU2726416C2 |
